Compare Smith & Nephew plc (SNN) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Unilever plc — how do they compare? Smith & Nephew plc trades at $27.22 (market cap $11.10B), while Unilever plc trades at $62.09 (market cap $131.63B). The key difference: Unilever plc is far larger — about 11.9× Smith & Nephew plc's market cap, and Unilever plc pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Unilever plc for 112 Days on average.
| SNN | UL | |
|---|---|---|
Market Cap | $11.10B | $131.63B |
Volume | 1,051,703 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $37.17 | $74.59 |
52-Week Low | $26.42 | $55.05 |
Typical Hold Time | 121 Days | 112 Days |
Enterprise Value | $14.13B | $156.65B |
Dividend Yield | 2.95% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Unilever (UL) trades at $61.98, up 1.64% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is mixed with 24% buy ratings amid ongoing business restructuring including the planned McCormick food division sale.
UL offers defensive exposure with emerging market growth potential but faces execution risks from portfolio streamlining. The stock presents moderate valuation (P/E 21.59) with cash flow stability, though recent earnings underperformance and regulatory scrutiny on the McCormick deal warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
